Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial
GLP-1 users in Canada report a 20 percent drop in restaurant visits, a 25-30 percent drop in eating sweets, chocolate and baked goods, and an almost 20 percent drop in alcohol consumption
Some clients feel benefits immediately, while others notice improvements over the next several hours to a day, depending on hydration status and nutrient levels
Reverter Fundaci, IMIM Research Summary: The use of dried blood spots (DBS) for sample collection is increasingly attracting the interest of the antidoping analytical community because of their multiple advantages [1]
Looking forward, the approval of orforglipron in 2026 is a key potential upside catalyst for Lilly shares